Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure

OBJECTIVES: Telavancin is approved in Europe for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus when other alternatives are not suitable. The approved European prescribing information contraindicates the use of telavancin in patients with severe renal imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, A., Rubinstein, E., Corey, G. R., Stryjewski, M. E., Barriere, S. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023300/
https://www.ncbi.nlm.nih.gov/pubmed/24398339
http://dx.doi.org/10.1093/jac/dkt490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023300/
https://www.ncbi.nlm.nih.gov/pubmed/24398339
http://dx.doi.org/10.1093/jac/dkt490

Ejemplares similares